No Fast Route To EU Market For Dova's Avatrombopag
Dova’s avatrombopag, which was recently approved in the US under priority review, has been refused an accelerated assessment in the EU.
Dova’s avatrombopag, which was recently approved in the US under priority review, has been refused an accelerated assessment in the EU.